Circassia Pharmaceuticals (NIOX) Stock Statistics & Valuation Metrics

Circassia Pharmaceuticals has a market cap or net worth of £305.88M. The enterprise value is 278.94M.

Circassia Pharmaceuticals has 417,871,600 shares outstanding. The number of shares has decreased by -2.65% in one year.

Circassia Pharmaceuticals’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 5.44%.

The current PE Ratio of Circassia Pharmaceuticals is 58.1. Circassia Pharmaceuticals’s PEG ratio is -1.09.

In the last 12 months, Circassia Pharmaceuticals had revenue of 41.80M and earned 3.70M in profits. Earnings per share was 0.01.

In the last 12 months, operating cash flow was 18.70M and capital expenditures 100.00K, giving a free cash flow of 18.80M billion.

Circassia Pharmaceuticals pays an annual dividend of 1.25p, resulting in a dividend yield of 2.96%

Circassia Pharmaceuticals upcoming earnings date is Mar 24, 2026, Before Open (Confirmed).

Circassia Pharmaceuticals as a current ratio of 2.60, with Debt / Equity ratio of 1.86%

In the past 12 months, Circassia Pharmaceuticals has paid 4.40M in taxes.

Circassia Pharmaceuticals EV to EBITDA ratio is 20.83, with an EV/FCF ratio of 15.68.

Circassia Pharmaceuticals has £11.80M in cash and marketable securities with £1.20M in debt, giving a net cash position of £10.60M billion.

Gross margin is 61.96%, with operating margin of 18.42%, and net profit margin of 8.85%.

The average price target for Circassia Pharmaceuticals is £76.00, which is 11.43% higher than the current price. The consensus rating is Hold